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Real-time PCREquine infectious anemia virus (EIAV) infection is distinctive in that it causes a rapid onset of clinical disease
relative to other retroviruses. In order to understand the interaction dynamics between EIAV and the host
immune response, we explored the effects of EIAV and its S2 protein in the regulation of the cytokine and
chemokine response in macrophages. EIAV infection markedly altered the expression pattern of a variety of
pro-inﬂammatory cytokines and chemokines monitored in the study. Comparative studies in the cytokine
response between EIAV17 and EIAV17ΔS2 infection revealed that S2 enhances the expression of IL-1α, IL-1β,
IL-8, MCP-2, MIP-1β and IP-10. Moreover, S2 speciﬁcally induced the expression of the newly discovered
cytokine, IL-34. Taken together, these results may help explain the effect of cytokine and chemokine
dysregulation in EIAV pathogenesis and suggest a role of S2 in optimizing the host cell environment to
promote viral dissemination and replication.
© 2009 Elsevier Inc. All rights reserved.Introduction
Equine infectious anemia (EIA), commonly known as swamp fever,
is a worldwide disease of equids. The causative agent of EIA is equine
infectious anemia virus, or EIAV (genus lentivirus, family Retroviri-
dae), closely related to human immunodeﬁciency virus (HIV). EIAV is
transmitted primarily through biting ﬂies, such as the blood-feeding
horseﬂies and deerﬂies (Foil and Issel, 1991). Natural or experimental
infection of horses with EIAV causes a rapid, rather than the very slow
disease progression that is characteristic of most lentiviral infections
(Cheevers and McGuire, 1985). The clinical course of EIAV infection is
divided into three distinct stages: acute, chronic and inapparent. The
symptoms associated with acute disease usually occur within 1 to
4 weeks after infection and are of short duration. Symptoms of acute
EIA include fever, depression, rapid weight loss, anemia, thrombocy-
topenia, and high levels of viremia (Oaks et al., 1998; Russell et al.,
1999). Some infections progress to chronic EIA, in which infected
animals develop recurrent cycles of fever, associated with high viral
load and clinical signs similar to the acute phase (McGuire et al., 1990;
Sellon, 1993). Recurrences appear during an interval of 6 to 8 months
and are interspersed with normal clinical periods (weeks or months).
Approximately 8 to 12 months post-infection, more than 90% of
infected horses progress to a life-long inapparent carrier stagell rights reserved.characterized by very low viral loads and lack of clinical signs (Li et
al., 2003; Sellon et al., 1994). The inapparent carrier stage seems to be
associated with the establishment of strict immunological control
over virus replication. Inapparent carriers are a constant source of
transmission to uninfected horses (Hammond et al., 2000; Issel et al.,
1982).
In addition to encoding the gag, pol and env genes common to all
retroviruses, EIAV encodes a dUTPase in the pol gene that is required
for productive viral replication in non-dividing cells such as macro-
phages (Lichtenstein et al., 1995; Threadgill et al., 1993). EIAV also
encodes four regulatory/accessory proteins: Tat, Rev, Ttm and S2. The
S2 gene, located in the pol–env intergenic region encodes a 65 amino
acid 7 kDa protein, which is synthesized in the late phase of the viral
life cycle (Carroll and Derse, 1993; Schiltz et al., 1992). S2 is mainly
localized in the cytoplasm and may interact with the EIAV Gag
precursor in cell culture (Yoon et al., 2000). The S2 open reading
frame is highly conserved, being found in all published EIAV
sequences, indicating that it carries a vital function in vivo (Leroux
et al., 2004; Li et al., 2000). In vitro, S2 is not required for viral
replication in cultured equine monocyte derived macrophages
(eMDM), the natural target for EIAV replication (Li et al., 1998).
However, the biological importance of S2 in viral pathogenesis has
been demonstrated by experimental infection in Shetland ponies
(Fagerness et al., 2006; Li et al., 2000). Ponies infected with a virus
derived from the highly virulent molecular clone, EIAV17, experience
severe febrile episodes accompanied by a signiﬁcant decrease in
platelet count and an increase in viral load, similar to those seen in
Fig. 1. (A) Growth kinetics of viral stocks. eMDMs were infected at a multiplicity of
infection (MOI) of 3 with EIAV17 (○), EIAV17ΔS2 (▴), or mock-infected (■). Culture
media were harvested at the indicated time points after infection and viral replication
was monitored by measurement of reverse transcriptase (RT) activity. (B) Real time
PCR detection of viral mRNA transcripts during the experiment depicted in Fig. 2. Three
sets of eMDM cells were infected with EIAV17 (○) or EIAV17ΔS2 (▴) at an MOI of 3. RNA
from infected cells were collected at the indicated time points then subjected to reverse
transcription and ampliﬁed in the presence of EIAV speciﬁc primers. Viral mRNA was
normalized against 18S mRNA levels. The error bars indicate the standard deviation
from three horses (n=3). The data shown in Panels A and B are from separate
experiments.
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molecular clone lacking a functional S2 protein (EIAV17ΔS2) display a
decrease in viral replication and fail to develop any clinical signs of
disease (Fagerness et al., 2006). Despite its essential role, the
mechanisms by which S2 inﬂuences EIAV pathogenesis are not
understood. Since S2 does not display signiﬁcant sequence homology
with any other retroviral or cellular proteins, it has been difﬁcult to
predict its mode of action.
Macrophages are considered the predominant cell type for EIAV
infection. It has been shown that blood monocytes are permissive for
EIAV, but differentiation of monocytes into macrophages is a
prerequisite step for EIAV replication (Maury, 1994; Schiltz et al.,
1992; Sellon et al., 1996). In addition to the role as reservoirs, infected
monocytesmay serve as vehicles capable of disseminating the virus to
macrophage-rich organs such as the spleen, liver and kidney, which
are the primary sites associated with high levels of EIAV replication in
persistently infected horses (Oaks et al., 1998). Cells of the monocyte/
macrophage lineage play an important role in the immune response
against pathogens, these cells produce soluble factors such as
cytokines and chemokines, which can orchestrate the immune
response to infection.
During EIAV infection, serum levels of tumor necrosis factor alpha
(TNF-α), transforming growth factor beta (TGF-β) and interferon
alpha (IFN-α) which can act as negative regulators of platelet
production are increased before the clinical onset of thrombocytope-
nia (Tornquist et al., 1997). In addition, eMDMs infected with EIAV17
displayed signiﬁcantly increased expression of interleukin-1 (IL-1) α,
IL-1 β, IL-6, IL-10 and TNF-α early during infection (0.5–1 h post-
infection) suggesting a role of these pro-inﬂammatory cytokines
during the initial response to EIAV infection (Lim et al., 2005). To
examine the underlying immune mechanisms in the pathogenesis of
EIAV and the role, if any, of S2 inmodulating this response, we studied
the expression proﬁles of cytokines/chemokines over time in
response to EIAV infection in eMDMs.
EIAV serves a valuable animal model not only as a macrophage-
tropic lentivirus, but also as a model for host immune control of
lentiviral infection. Although S2 is not the sole virulence determinant
for EIAV, elucidating the speciﬁc role(s) of S2 in disease expression
will advance our understanding of the patho-mechanism of lentiviral
infection.
Results
Assay validation
PCR efﬁciency for each primer/probe set was determined from the
slope of the standard curve generated from the serial dilutions of
cDNA. A standard curve slope of−3.32 indicates a PCR reaction with
100% efﬁciency. Generally, efﬁciency between 90% and 110% is
considered acceptable. For all the primer/probe sets, PCR efﬁciencies
ranged between 93 and 105%. Moreover, the R2 and standard
deviation for each primer/probe set was N0.99 and ≤0.13 respec-
tively, indicating overall assay precision (Table S2, supplementary
material). To account for differences in PCR efﬁciencies, the Pfafﬂ
method was used to determine the relative expression of the target
genes (Pfafﬂ, 2001). A single band of expected size was obtained using
each primer/probe set (Fig. S1, supplementary material). In addition
sequence analysis conﬁrmed the ampliﬁcation of the target sequences
(data not shown).
Viral infectivity and mRNA expression
Viral infectivity of the puriﬁed stocks was veriﬁed by reverse
transcriptase assay. Viral stocks remained infectious after puriﬁcation
and concentration and showed similar replication kinetics at an MOI
of 3 (Fig. 1A). These data are in agreement with previously publishedreports that S2 is not required for efﬁcient EIAV replication in cultured
cells. During the course of EIAV infection in eMDMs, we also
monitored the levels of viral transcription by real time PCR. As
shown in Fig. 1B, delta cycle threshold (ΔCt) values were gradually
decreased over time, indicating an increase in viral gene transcription.
No differences in the levels of viral transcripts were observed between
wild-type and S2-deleted viruses during the cytokine/chemokine
time course experiment. Moreover, no evidence of contamination
with wild-type sequences was observed during infection with the
mutant virus (data not shown).
Cytokine/chemokine expression in EIAV infected eMDMs
To study the expression proﬁles of a set of equine cytokines and
chemokines in response to EIAV infection and examine the role of S2
in regulating this response, we monitored the mRNA expression of
12 cytokines known to play a role in the immunopathogenesis of
retroviral infections. As shown in Fig. 2, there was a clear effect in
the cytokine and chemokine mRNA levels in response to EIAV
infection. Analysis of the expression data (Table 1) shows that
following EIAV17 infection, there was a statistically signiﬁcant
increase (pb0.05) in the expression of IL-1β, IL-8, IL-34 and MCP-
2 from days 1 to 4 post-infection compared with the mock-infected
control. Levels of TNF-α, MCP-1, MIP-1β and IP-10 mRNA were
signiﬁcantly upregulated from days 2 to 4 post-infection. IL-6 and
MIP-1α were only induced signiﬁcantly above the baseline levels at
days 3 and 4 post-infection. Also, during the ﬁrst 3 days post-
infection, the levels of IL-1α were signiﬁcantly increased relative to
Fig. 2. Time course of cytokine/chemokine mRNA expression in eMDM infected with EIAV17 (○), EIAV17ΔS2 (▴), or mock-infected (■). Data were analyzed using the Pfafﬂmethod.
All values were normalized to the endogenous control 18S or b-actin, and represent the log2 mean fold change in expression (relative to mock-infected control). Error bars
represent±SEM from six different horses (n=6).
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expression of IL-10 at any of the time points examined, although
there was a subtle decrease in expression compared with the control
(Fig. 2).Table 1
Comparison of cytokine/chemokine gene expression in EIAV17b and EIAV17bΔS2 infected eM
Cytokine EIAV17b and EIAV17bΔS2
1dpi 2dpi
Mean17b MeanΔS2 p value Mean17b MeanΔS2 p va
IL-1alpha 1.39 0.63 0.101 1.04a 0.27b 0.02
IL-1beta 2.17 1.56 0.103 2.31a 1.28b 0.00
IL-6 0.15 −0.08 0.337 0.44 0.20 0.32
IL-8 1.68a 1.00b 0.011 2.45a 1.36b 0.00
IL-10 0.05 0.32 0.689 −0.22 0.05 0.67
IL-34 0.91a 0.22b 0.005 1.30a 0.23b 0.00
TNF-alpha 0.22 −0.03 0.086 0.56 0.27 0.15
MCP-1 0.48 0.40 0.456 0.87 0.60 0.42
MCP-2 1.65a 0.75b 0.020 2.66a 1.29b 0.00
MIP-1alpha −0.10 −0.20 0.642 0.26 0.12 0.61
MIP-1beta 0.14 −0.02 0.554 0.70 0.37 0.13
IP-10 0.47 0.47 0.995 1.98a 0.87b 0.00
Values represent the mean log2 fold change of infected relative to mock-infected control. Ind
control (Mean17 column), EIAV17ΔS2 vs. mock infected control (Mean17ΔS2 column) and EIAV
expression compared to the control (control values are constant and are not presented in th
indicate signiﬁcant differences between EIAV17 and EIAV17ΔS2. Results were considered sig
EIAV17ΔS2 comparison.Comparative analysis in the cytokine response between the wild-
type virus and the S2-deleted virus showed that there is a pattern of
enhancement in the cytokine/chemokine response in eMDMs
infected with the wild-type virus (Fig. 2). There was a statisticallyDM.
3dpi 4dpi
lue Mean17b MeanΔS2 p value Mean17b MeanΔS2 p value
4 1.65 0.93 0.203 1.52 0.92 0.442
0 1.83 0.93 0.060 1.79 0.90 0.280
7 0.93 0.33 0.138 1.58 0.98 0.334
0 3.39a 2.05b 0.018 4.25 3.32 0.278
5 −0.83 −0.32 0.331 −0.32 −0.53 0.630
8 1.20a −0.14b 0.000 1.36a 0.14b 0.006
9 0.70 0.32 0.216 1.13 0.64 0.315
1 0.95 0.53 0.290 0.88 0.64 0.572
1 3.03a 1.47b 0.008 3.65 2.31 0.072
9 0.90 0.32 0.099 1.59 0.98 0.157
9 2.06a 1.14b 0.050 3.50 2.61 0.172
3 2.68a 0.86b 0.016 4.45 2.58 0.258
ependent t-tests were conducted to compare mean values for EIAV17 vs. mock infected
17 vs. EIAV17ΔS2. Bolded values indicate statistically signiﬁcant (pb0.05) changes in gene
e table; p-values for these comparisons are not presented in the table). Different letters
niﬁcantly different when pb0.05. p-values shown in the table describe the EIAV17 vs.
220 L. Covaleda et al. / Virology 397 (2010) 217–223signiﬁcant difference in gene expression of IL-8 and MCP-2 from days
1 to 3 post-infection (pb0.05) between the EIAV17 and S2 mutant
viruses. Moreover, levels of IL-1α and IL-1β mRNA were signiﬁcantly
increased in cells infected with EIAV17 compared with S2-deleted
virus at day 2, MIP-1β at day 3 and IP-10 at days 2 and 3 post-infection
(Table 1).
In the course of studying cytokine and chemokine proﬁles during
EIAV infection, IL-34 was identiﬁed in an equine oligo microarray
study to be upregulated upon EIAV infection (unpublished data).
Therefore, we examined the gene expression proﬁle of this newly
discovered cytokine. When eMDMs were infected with the wild type
virus, IL-34was upregulatedmore than 2-fold during the course of the
infection with signiﬁcant differences in gene expression compared
with mock-infected or EIAV17ΔS2 infected cells (pb0.01) at all time
points tested. Moreover, in contrast to other tested genes, IL-34mRNA
levels in cells infected with EIAV17ΔS2 were similar to those observed
in mock-infected control at all time points.
Since out-bred horses were used in the study (n=6), there was
considerable donor to donor variation in the cytokine response to
EIAV infection. The greatest donor to donor variability in the response
between EIAV17 and EIAV17ΔS2 was observed at day 4 post-infection.
Thus, although there was not an overall statistically signiﬁcant
difference in the induction of IL-8, MCP-2, MIP-1β and IP-10 between
the two viruses at day 4 post-infection, there was a marked difference
in the response among horses. For example, IP-10 gene expression
varied from 1 to 18 fold in cells infected with EIAV17 compared with
EIAV17ΔS2 (data not shown).
Examining the kinetics of gene expression shows that IL-6, IL-8,
TNF-α, MCP-2, MIP-1α, MIP-1β and IP-10 upregulation was minimal
early during infection but gradually increased until the last time point
examined. Levels of IL-1β were gradually decreased over time but
signiﬁcantly higher than the control at day 4 post-infection. IL-34
transcripts levels were signiﬁcantly upregulated early in infection and
remained steady during the course of infection. For IL-10 there was a
subtle, although not statistically signiﬁcant decrease in expression
relative to the control. No signiﬁcant changes in MCP-1 expression
were detected over time (Fig. 2).
To clearly delineate the effect of S2 in cytokine dysregulation, we
also analyzed the overall cytokine and chemokine response during
EIAV infection. Similarly, the results showed that there is a signiﬁcantFig. 3. Overall cytokine and chemokine expression of eMDM infected with EIAV17 ( ) or EIA
mock-infected control; mean was obtained by using means per date divided by the number
mixed model (LMM) was used to determine whether or not signiﬁcant differences occurreeffect of EIAV infection in the cytokine/chemokine response in eMDM
(Fig. 3). eMDM infection with EIAV17 signiﬁcantly upregulated the
mRNA expression of IL-1α and β, IL-6, IL-8, IL-34, TNF-α, MIP-1β,
MCP-1, MCP-2 and IP-10 (p=0.00) and MIP-1α (p=0.02) relative to
the mock-infected cells. Moreover, the presence of S2 strongly
enhanced mRNA expression of IL-1α, MIP-1β, IP-10 (p=0.01), IL-
1β, IL-8, IL-34 and MCP-2, (p=0.00) compared with the EIAV17ΔS2
virus. However, the levels of IL-6, IL-10, TNF-α, MCP-1 and MIP-1α
showed no statistically signiﬁcant changes overall during infection
(pN0.05) compared with S2 deleted virus.
Discussion
A main feature of lentiviral infection is dysregulated expression
of cytokines and chemokines. During the course of HIV, SIV, and FIV
infections, cytokines are known to modulate viral replication,
persistence and disease progression in the host (Dean and Pedersen,
1998; Kedzierska et al., 2003; Orandle et al., 2001). The modulation
of the cytokine/chemokine response during the course of EIAV
infection has not been as fully elucidated. It has been shown that
early during infection (0.5–1 h post-infection) there is a pro- and
anti-inﬂammatory response to EIAV infection in vitro (Lim et al.,
2005), however the dynamics of cytokine response during the
course of EIAV replication in horses is unknown. Changes in
cytokine and chemokine levels during the course of EIAV infection
could have a major impact on the immune system, inﬂuencing
pathogenesis by enhancing or suppressing EIAV replication as well
as favoring the formation of infected cell reservoirs. We undertook
this study to further examine the effect of EIAV in modulating the
cytokine and chemokine response in macrophages during the
course of infection and to determine if the EIAV S2 protein has a
role in modulating this response. Our results conﬁrm that EIAV
induces a strong pro-inﬂammatory response in eMDM and that S2
enhances this response. In light of the clearly demonstrated role of
S2 in disease expression (Fagerness et al., 2006; Li et al., 2000) it is
possible that a robust pro-inﬂammatory response is advantageous
for the virus in the infected animal. In fact, pro-inﬂammatory
cytokines/chemokines such as IL-1, IL6, IL-8, TNF-α and IP-10,
among others are known to stimulate HIV replication (Ott et al.,
1998; Lane et al., 2003).V17ΔS2 (■). Bars represent the overall mean log2 fold change in expression relative to
of observed dates. Error bars represent±SEM from six different horses (n=6). Linear
d. ⁎⁎, indicates pb0.01.
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IL-1α, IL-1β, IL-6, IL-8, IP-10, IL-34, MCP-1, MCP-2, MIP-1α and MIP-1β
in EIAV-infected eMDM relative to uninfected controls. These results
correspond to studies of EIAV infected foals where increased levels of
TNF-α and INF-α are found in associationwith high levels of viremia and
are increased in the serum and bone marrow just before the onset of
thrombocytopenia (Tornquist et al., 1997). IL-1 β and IL-8 are also
associatedwithmarked thrombocytopenia (Bozza et al., 2008);whether
or not dysregulation of these cytokines contributes to the development
of thrombocytopenia during EIAV infection needs to be determined.
IL-10 was the only anti-inﬂammatory cytokine monitored in the
study. IL-10 strongly inhibits the production of a wide variety of
inﬂammatory mediators in macrophages, T cells and B cells (de Waal
Malefyt et al., 1991; Moore et al., 2001) and IL-10 decreases HIV
replication in macrophages (Akridge et al., 1994). In our study IL-10
expression was not increased by EIAV infection; in fact there was a
subtle decrease relative to the control. This result corroborates our
ﬁndings that EIAV replication favors the induction of a pro-
inﬂammatory response and that at least during the ﬁrst days post-
infection, this response is unlikely to have an antiviral effect.
EIAV infection also strongly stimulated gene expression levels of the
chemokines IP-10, IL-8, MCP-1, MCP-2, MIP-1α and MIP-1β during the
course of infection. The up-regulation of chemokine levels during EIAV
infection could explain the accumulation of lymphocytes and macro-
phages in the spleen, lymph nodes, lungs and other tissues in EIAV
infected horses (McGuire et al., 1990) and could play an important role
in disease progression. Increased IP-10 and IL-8 expression during HIV
infection stimulates viral replication in macrophages and T cells (Lane
et al., 2003, 2001). Moreover, dysregulation of theses chemokines has
been implicated in the intensity and progression of HIV disease (Kinter
et al., 1998; Reinhart, 2003; Schmidtmayerova et al., 1996).
AlthoughMIP-1α andMIP-1β are closely related pro-inﬂammatory
chemokines, they have distinctive biological properties. Both strongly
induce chemotaxis of monocytes and macrophages and are potent
pyrogens (Maurer and von Stebut, 2004; Menten et al., 2002; Minano
et al., 1996). MIP-1α but not MIP-1β suppresses cell proliferation of
granulocyte-macrophage (CFU-GM), erythroid (BFU-E) and multipo-
tential (CFU-GEMM) progenitors from bone marrow cells in vivo and
in vitro (Maze et al., 1992). Interestingly, MIP-1β acts speciﬁcally to
block the inhibitory effect of MIP-1α, suggesting a synergy between
these two chemokines to regulate proliferation of myeloid progenitor
cells (Broxmeyer et al., 1993, 1991).
Analysis of the role of S2 in cytokine/chemokine expression
indicates that S2 plays an overall enhancing role in the upregulation of
proinﬂammatory cytokines and chemokines. S2 had a signiﬁcant
effect on expression of IL-1α, IL-1β, MIP-1β, IP-10, MCP-2, and IL-8.
The difference in expression levels between S2-deleted and the
parental virus was not signiﬁcant for IL-6, TNF-α or MIP-1α, although
cytokine expression was somewhat decreased for the S2-deleted
virus. These results, together with in vitro studies of Lim et al. (2005)
that describe a role for EIAV SU in the induction of proinﬂammatory
cytokines in eMDM, and Payne et al. (2004) and Fagerness et al.
(2006) that reveal roles of SU and S2, respectively, in disease
expression suggest a scenario whereby EIAV SU and S2 act in concert
to produce a robust proinﬂammatory cytokine response that
promotes vigorous virus replication, fever and thrombocytopenia.
IL-34 is a newly discovered cytokine without signiﬁcant amino acid
sequencehomology toother cytokinesorproteins. IL-34 is expressed in a
wide variety of tissues including liver, kidney, thymus, brain and spleen.
In vitro, IL-34 speciﬁcally binds to monocytes and stimulates their
proliferation and/or survival. In addition, IL-34 promotes the differen-
tiation of bone marrow cells into a macrophage progenitor known as
colony-forming unit-macrophage (CFU-M), which in turn give rise to a
homogenous population of macrophages (Lin et al., 2008). At the amino
acid sequence level, equine IL-34 shares 85%, 75% and 71% pairwise
sequence identity with bovine, human and mouse, respectively.Our results clearly showed that EIAV infection of eMDM increased
the expression of IL-34. Since the S2-deleted virus failed to increase
themRNA levels above the baseline, this indicates a speciﬁc role for S2
in the upregulation of mRNA levels of this cytokine during infection.
Interestingly, among all the cytokines and chemokines tested, IL-34
was the only cytokine to be solely affected by the presence of S2.
These data underline the need for additional studies to determine the
role, if any, of S2 in monocyte proliferation and survival through
upregulation of IL-34 expression particularly as monocyte differenti-
ation into macrophage is a prerequisite for a productive EIAV
infection. Interestingly, IL-34 promotes the formation of monocyte/
macrophage lineage cells in the bone marrow, so it will be worth
testing whether or not S2 has an essential role in regulating the
proliferation of macrophage progenitors. A modulation of monocyte/
macrophage lineage proliferation could in turn increase the pool of
target cells available for infection having a profound effect in the
pathogenesis of EIAV infection. In contrast with HIV, SIV and FIV
infection where there is a suppression of bone marrow granulocyte/
macrophage progenitor cells (Linenberger et al., 1991; Prost et al.,
2008; Steinberg et al., 1991), EIAV is unique in that during the course
of infection there is not an apparent inhibitory effect in the formation
of granulocyte/macrophage progenitor cells (Swardson et al., 1992).
In summary, our study indicates that S2 is not solely responsible
for the modulation of the cytokine responses during EIAV infection
but supports the possibility of S2 as a contributing factor in cytokine
dysregulation, exacerbating disease progression. Cytokine enhance-
ment by S2 may promote a suitable cellular environment that is likely
to promote viral replication and dissemination, having a major impact
in viral pathogenesis and disease progression.
Materials and methods
Monocyte-derived macrophage cell culture
Whole blood was collected from six adult EIA-negative healthy
horses and centrifuged at 2100 rpm for 30 min to separate the buffy
coat, which was then diluted 1:3 with Hank's balance salt solution
(HBBS) containing 2 mM EDTA. Fifteen ml of endotoxin-free
Histopaque-1077 (Sigma-Aldrich) was slowly layered underneath
20 ml of diluted buffy coat and centrifuged at 2100 rpm for 30 min at
room temperature. Peripheral bloodmononuclear cells (PBMCs) were
harvested from the interface and washed by centrifugation at
1000 rpm for 10 min at 4 °C in cold endotoxin-free Alsever's solution
(0.1M D-glucose, 0.027 M sodium citrate, 0.002 M citric acid, 0.07 M
sodium chloride, pH 6.1) containing 1% penicillin-streptomycin, to
remove platelets. Residual erythrocytes were lysed by incubationwith
5 ml ACK lysis buffer (Invitrogen) for 3 min at 37 °C. After washing
three times with 50 ml Alsever's solution, PBMCs were resuspended
in RPMI 1640 medium supplemented with 10% heat-inactivated
horse serum, penicillin (100 IU/ml), streptomycin (100 μg/ml), and
L-glutamine (2 mM). For monocyte isolation by plastic adherence,
12×106 PBMC per well were seeded into 12-well plates (BD Falcon)
and allowed to adhere overnight in a 37 °C humidiﬁed 5% CO2
incubator. Nonadherent cells were removed by gently washing the
plates, twice, with prewarmed RPMI complete media and the
remaining adherent monocyte-enriched cells were allowed to
differentiate for further 48 h before infection. All reagents were
screened and found negative for endotoxin and mycoplasma
contamination using the Limulus Amebocyte lysate kit (Associates
of Cape Cod) and MycoFind Kit (Clongen laboratories) respectively.
Virus preparations
Virus stocks were generated as previously described (Lim et al.,
2005). Brieﬂy, D17 cells were transfected with 10 μg of the molecular
clones EIAV17 or EIAV17ΔS2 plasmids by using the calcium phosphate
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used to infected eMDMs. Culture supernatants collected from 7 to
15 dpi, were removed from infected eMDMs and cleared of cell debris
by low-spin centrifugation. Virus stocks were assayed for RT activity
as a measure of virus replication. Virus stocks were puriﬁed and
concentrated via ultraﬁltration using a Vivaﬂow 200 tangential ﬂow
system with a 100 kDa MWCO ﬁlter (Sartorius). After ultraﬁltration,
maintenance of virus infectivity was conﬁrmed by growth in eMDMs
and RT activity. No detectable levels of endotoxin were present in the
puriﬁed virus stocks. Viral infectious titers were determined by the
Reed–Muench formula after infecting eMDMs with 10-fold serial
dilutions of the virus in sextuplicates over 2 weeks of infection.
Infection of eMDM
Three days post-plating, eMDM were mock infected (with cell
culturemedia used to grow the cells), infectedwith EIAV17 or EIAV17ΔS2
at a multiplicity of infection (MOI) of 3 to achieve a near synchronous
infection. Supernatants and cell extractswere collected fromdays 1 to 4
post-infection. Viral replication in the cultures was monitored for RT
activity, cytopathic effect (CPE) and viral mRNA transcription in
samples collected at various time points post-infection.
RNA isolation and cDNA synthesis
At each time point (1–4 dpi), cells were harvested in RLT buffer
(QIAGEN) and cell pellets were stored at−80 °C until ready for RNA
isolation. Total RNA was isolated using the RNeasy kit from Qiagen,
including DNase I digestion according to manufacturer's instructions.
RNAwas further assessed for quality and concentration using theNano
6000 assay on the Agilent 2100 Bioanalyzer. cDNA was synthesized
using the SuperScript Vilo cDNA Synthesis Kit (Invitrogen).
Real time PCR
TaqMan and SYBR Green based assays were used to analyze gene
expression levels of 12 selected cytokine/chemokine target genes
(Table S1, supplementary material). TaqMan real time PCR reactions
were performed in a 10-μl total volume containing 0.5 μl of cDNA, 5 μl
of EXPRESS qPCR SuperMix with premixed ROX (Invitrogen), 0.5 μl of
ﬂuorescent primer/probe mix, and 4 μl of DEPC-treated water. SYBR
Green real time PCR reactions contained 5 μl of SYBR Greener qPCR
with premixed ROX (Invitrogen), 200 nM of the primer mix, and
DEPC-treatedwater. Ampliﬁcationwas carried out using the following
parameters: 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of
95 °C for 15 s and by 60 °C for 30 s. A dissociation stage was included
for SYBR Green real time PCR to conﬁrm the ampliﬁcation of a single
product. All RT reactions, including no-template controls, were run in
triplicate on an ABI 7900HT real-time PCR system. Data were collected
and analyzed with the SDS 2.3 software.
Data analysis and validation of chemokines TaqMan probes
The Pfafﬂmethod (Pfafﬂ, 2001) was used to calculate relative fold
changes in cytokine/chemokine gene expression between mock-
infected and infected samples. Data were ﬁrst normalized to the
endogenous control 18S rRNA or beta-actin and the mock-infected
samples from each time point were used as the calibrator control.
TaqMan primer/probe sets for IL-1α, IL-1β, IL-6, IL-8, TNF-α and18S
have been previously described and validated (Allen et al., 2007).
TaqMan primer/probe sets for MCP-1, MCP-2, MIP-1α, MIP-1β, and
IP-10 were obtained from Applied Biosystems. TaqMan probes and
primers for SYBR Green real time PCR were designed to span at least
one exon–exon junction to prevent ampliﬁcation of genomic
sequences. TaqMan probes were 5′ labeled with 6-carboxyﬂuorescein
(FAM) and 3′with a nonﬂuorescent quencher (NFQ). RT-PCR productswere separated by 2% agarose gel electrophoresis to conﬁrm product
size and speciﬁcity of each primer/probe set. Fragments were also
analyzed by sequence to validate the identity of the PCR products. PCR
efﬁciency from each primer/probe set was determined by performing
a 6-log dilution range from 3 different cDNA samples. Each dilution
was run in triplicate.
Viral RNA expression
SYBR Green real time PCR was used to detect viral transcripts with
speciﬁc primers (forward 5′-CGGGACAGCAGAGGAGAACT-3′ and
reverse 5′-CAATCC CTAGAGACCTCAGGAAACAC-3′) spanning the
splice site used to generate the single spliced, tricistronic mRNA
that encodes Tat, S2 and Env. In addition, speciﬁc primers bearing the
S2 mutation (forward 5′-AACACAGGAGGACAGGAAGCA-3′ and re-
verse 5′-TTACCCCTTTACCAAATACTCCCATA-3′) were used to screen
for contamination with wild-type sequences.
Statistical analysis
Fold changes for each cytokine/chemokine mRNA response were
normalized by log-2 transformation prior to statistical analysis (data
were not normally distributed). Transformed datawere then analyzed
using the Linear Mixed Model (LMM) (Repeated Measures-Type III
sum of squares and diagonal repeated covariance) procedure for
comparisons of changes in gene expression among treatments and
across time. In this analysis, “horse” is considered the random factor
and “day”, “treatment” and “day×treatment” interactions considered
as the ﬁxed factors. The transformed fold changes corresponded to the
response variable. This analysis allows for unsystematic variability of
the data and provides greater power to detect effects. In this method,
the covariance of errors is estimated and then used to constrain the
error covariance matrix to derive the mean squares estimates of the
effects. This method provides a way for modeling error structures
among the repeated dependent variables and avoids Type I errors, it is
also used for unbalanced sets of data. In addition, independent t-tests
were conducted on each separate date to compare mean values
between EAIV17 vs. mock infected control, EAIV17 vs. EIAV17ΔS2 and
EIAV17ΔS2 vs. mock-infected control and to determine differences in
gene expression that occurred across treatments on each day. The
statistical package SPSS 15.0 (SPSS Inc. 2007) was used to perform
these analyses. All data were expressed as mean value (log2)±S.E.M.
Results were considered signiﬁcantly different when pb0.05.
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